Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovative Medicine: The Balance Between Benefits and Costs

This article was originally published in RPM Report

Executive Summary

There are two ongoing debates around the impacts of innovation in medicine: to what degree are rising health care costs attributable to new technologies and are those costs worth the outcomes benefit? “New or expensive” shouldn’t be the sole criteria for judging whether we adopt new therapies as a society.

You may also be interested in...



Booby Prize: Why Replacing Patents With Prizes Would Harm Innovation

Presidential candidate Senator Sanders has proposed replacing patents with a government run scheme that offers prize money to innovators who create new medicines. This approach misunderstands the vital role of patents in society especially for new medicines. Using prizes for new medicines -- rather than patents -- risks assigning to the government the role of picking winners and losers in science.

NIH is the MVP of Biomedical Research: Why Getting Them More Resources the Right Way Matters

Sen. Warren is making headlines for proposing a “swear jar” to fund NIH with payments from drug manufacturers who settle fraud cases. That idea is based on faulty facts and worse logic – and is counterproductive for the goal of increasing spending on biomedical research.

Cure for Alzheimer's Disease: Cost or Value?

If the societal reaction to the costs to cure Hep C is any indicator, a potential cure for Alzheimer’s will surely stir controversy assuming breakthrough-level pricing. A financing solution may be the only way to reward developers for the value of the therapy and address the challenges facing insurers.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel